Homozygous Familial Hypercholesterolemia (HoFH) Latest Advances

Sitosterolemia: A Rare Cause of Severe Hypercholesterolemia in Children.

Journal: WMJ : official publication of the State Medical Society of Wisconsin

Published: August 20, 2026

Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Journal: Journal of the American Heart Association

Published: August 20, 2026

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal: Journal of atherosclerosis and thrombosis

Published: July 01, 2026

Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: June 30, 2026

The Spanish Atherosclerosis Society Dyslipidaemia Registry: Evolution, real-world evidence, and its role in precision medicine. Current status in 2026.

Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis

Published: June 17, 2026

When Cholesterol Can Kill at 20: Recognizing and Managing Homozygous Familial Hypercholesterolemia in the Young.

Journal: JACC. Case reports

Published: June 11, 2026

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

Journal: Circulation research

Published: June 04, 2026

Translating Lipoprotein Genetics Into New Therapies.

Journal: Circulation research

Published: June 04, 2026

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

Journal: European heart journal

Published: May 25, 2026

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Journal: Journal of clinical lipidology

Published: May 12, 2026

Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.

Journal: Expert opinion on therapeutic targets

Published: May 07, 2026

The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

Journal: Current atherosclerosis reports

Published: May 05, 2026

Homozygous Familial Hypercholesterolemia (HoFH) Latest Advances

Find the Latest Research About Homozygous Familial Hypercholesterolemia (HoFH)

Sitosterolemia: A Rare Cause of Severe Hypercholesterolemia in Children.

Sitosterolemia: A Rare Cause of Severe Hypercholesterolemia in Children.

Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.

Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.

The Spanish Atherosclerosis Society Dyslipidaemia Registry: Evolution, real-world evidence, and its role in precision medicine. Current status in 2026.

The Spanish Atherosclerosis Society Dyslipidaemia Registry: Evolution, real-world evidence, and its role in precision medicine. Current status in 2026.

When Cholesterol Can Kill at 20: Recognizing and Managing Homozygous Familial Hypercholesterolemia in the Young.

When Cholesterol Can Kill at 20: Recognizing and Managing Homozygous Familial Hypercholesterolemia in the Young.

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

Translating Lipoprotein Genetics Into New Therapies.

Translating Lipoprotein Genetics Into New Therapies.

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.

Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.

The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.

The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies.